An investigation of the apparent breast cancer epidemic in France: Screening and incidence trends in birth cohorts

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Junod, Bernard ^a,b   Zahl, Per Henrik ^c   Kaplan, Robert M ^d   Olsen, Jørn ^d   Greenland, Sander ^d,e  

^a Formindep   (France)

^b EHESP SCHOOL OF PUBLIC HEALTH   (France)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; DIAGNOSTIC ERROR; EPIDEMIC; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; BREAST TUMOR; INCIDENCE; MASS SCREENING; MIDDLE AGED; RISK FACTOR;

AGED; BREAST NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RISK FACTORS;

EID: 80053175037     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-401     Document Type: Article

References (47)

1. Guerin S, Doyon F, Hill C. The frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends. Bull Cancer 2009, 96(1):51-7.
2. World Health Oganization Attributable causes of cancer in France in the year 2. IARC Working Group Reports 2007, 3. WHO, Geneva, World Health Oganization.
3. Cancers-environnement. Expertise collective. INSERM. 2008, 907 pages.
4. Boer WP, de Koning H, van Oortmarssen G. Extraincidence caused by mammographic screening. The Lancet 1994, (343):979.
5. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 2006, 332:689-92. 10.1136/bmj.38764.572569.7C, 1410836, 16517548.
6. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009, 339:b2587. 10.1136/bmj.b2587, 2714679, 19589821.
7. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. JNCI 2002, 94(13):981-90.
8. Martinez-Alonzo M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res 2010, 12(4):R58. Epub 2010 Aug 3, 10.1186/bcr2620, 2949650, 20682042.
9. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008, 168(21):2311-6. 10.1001/archinte.168.21.2311, 19029493.
10. Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol 2004, 33:43-55. 10.1093/ije/dyg275, 15075144.
11. Gøtzsche PC. On the benefits and harms of screening for breast cancer. Int J Epidemiol 2004, 33:56-64. 10.1093/ije/dyh014, 15075145.
12. Freedman DA, Petiti DB, Robins JM. Rejoinder. Int J Epidemiol 2004, 33:69-73.
13. Welch HG. Screening mammography - A long run for a short slide?. N Engl J Med 2010, 363(13):1276-8. 10.1056/NEJMe1008369, 20860510.
14. Gøtzsche PC, Nielsen M. Screening for Breast Cancer with Mammography. Cochrane Database Syst Rev 2009, 7(4):CD001877.
15. Welch HG, Black WC. Overdiagnosis in Cancer. JNCI 2010, 102:605-13.
16. Centre d'epidemiologie sur les causes medicales de deces. , http://www.cepidc.vesinet.inserm.fr/
17. Remontet L, Esteve J, Bouvier AM Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Macé-Lesec'h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003, 51:3-30.
18. Parkin DM, Whelan SI, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. IARC Scientific Publication 143. Lyon IARC 1993, VII.
19. Evolution de l'incidence et de la mortalité par cancer en France de 1980 à 2005. Estimations à partir des données des registres du réseau FRANCIM et du CepiDCIM. Institut de la veille sanitaire. Janvier 2008, http://www.ecosante.fr/FRANFRA/141.html
20. Tamborini A. Menopause, THS et osteoporose post-menopausique: quoi de neuf?. Réalités en Gynécologie-Obstétrique 2008, 130:1-7. 3175690, 21941641.
21. Traitement hormonal substitutif de la menopause. Afssaps 2005, 68.
22. Com-Ruelle L, Dourgnon P, Jusot F, Lengagne P. Les problemes d'alcool en France: quelles sont les populations à risque. Questions d'economie de la sante. IRDS 2008, 1-6. N° 129.
23. De Saint Pol T. Evolution de l'obésité en France de 1981 à 2003: Les disparités entre milieux sociaux augmentent. Obésité 2007, (2):188-94.
24. Rochefort H, Rouesse J. Cancers du sein, incidence et prevention. Bull Acad Natle Med 2008, 192:161-74.
25. Laugier A. Annuaire de la cancérologie/radiothérapie et des imageries médicales en France (ACRIM). 2002, Paris.
26. Dubois G. Le depistage des cancers. Situation et perspectives en France. Acta Endoscopica 1992, 22:115-18.
27. http://lesrapports.ladocumentationfrancaise.fr/BRP/074000352/0000.pdf
28. Wait S, Schaffer P, Seradour B, Chollot M, Demay M, Dejouhanet S. Opportunistic breast cancer screening in France. Bull Cancer 1997, 84(6):619-24.
29. Kopans DB. The 2009 US Preventive Services Task Force (USPSTF) guidelines are not supported by science: the scientific support for mammography screening. Radiol Clin North Am 2010, 48(5):843-57. 10.1016/j.rcl.2010.06.005, 20868889.
30. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010, 363(13):1203-10. 10.1056/NEJMoa1000727, 20860502.
31. Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark. A comparative study. BMJ 2010, 340:c1241. 10.1136/bmj.c1241, 2844939, 20332505.
32. Autier P, Moniol M, Gavin A, Natten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011, 343:d4411. 10.1136/bmj.d4411, 3145837, 21798968.
33. Vainio H, Bianchini F, . editors IARC Handbook of Cancer Prevention Volume 7 Breast Cancer Screening. 2002, Lyon. IARC Press, editors.
34. Hofvind S, Sørum R, Thoresen S. Incidence and tumour characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncologica 2008, 47:225-31. 10.1080/02841860701518041, 17851868.
35. Kaplan RM, Saltzstein SL. Reduced mammographic screening may explain declines in breast carcinoma in older women. J Am Geriatr Soc 2005, 53(5):862-6. 10.1111/j.1532-5415.2005.53263.x, 15877565.
36. Mouquet MC, Cherie-Challine L, Marescaux C. L'analyse des séjours chirurgicaux au sein du PMSI:un nouvel indicateur pour l'observation des cancers. DRESS 2002, 27:1-32.
37. Aubard Y, Genet D, Eyraud JL, Clavere P, Tubiana-Mathieu N, Philippe HJ. Impact of screening on breast cancer detection. Retrospective comparative study of two periods ten years apart. Eur Gynaec Oncol J 2002, 23:37-41.
38. McKinnon NE. Breast Cancer mortality, Ontario, 1909-1947. The lack of any decline, and its significance. Can J Pub Health 1949, 40:257-69.
39. Welch HG, Black WC. Using Autopsy series to estimate "reservoir" for ductal carcinoma in situ of the breast: How much more breast cancer can we fin?. Ann Intern Med 127(11):1023-8. 19997.
40. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. Cancer 1984, 54:612-5. 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B, 6744199.
41. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985, 51:271-8. 10.1038/bjc.1985.39, 1977023, 3966983.
42. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987, 60:2751-60. 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M, 3677009.
43. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987, 56:814-9. 10.1038/bjc.1987.296, 2002422, 2829956.
44. Zahl PH, Strand GH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. BMJ 2004, 328:921-4. 10.1136/bmj.38044.666157.63, 390204, 15013948.
45. Zakrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 5 years after end of Malmo mammographic screening trial: Follow-up study. BMJ 2006, 332:689-92. 10.1136/bmj.38764.572569.7C, 1410836, 16517548.
46. Académie nationale de médecine. Analyse du rapport de la commission d'orientation sur le cancer. Académie de médecine. 2003, Paris.
47. Philip T, Kasparian C, Fagnani F, Moatti JP, Meunier A, Parodi AL, Mornex R, Paolaggi JB, Godeau P, Vacheron A, Dreux C, Dubois F, Junod B, Picard JD. Le dépistage du cancer du sein en France: bilan et limites Discussion. Bulletin de l'Académie Nationale de Médecine 2005, 189:321-39. n° 2.